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Abnormalities of fragile histidine triad (FHIT) and TP53 have been found frequently in nonsmall cell lung cancers. In the current study,
263 primary nonsmall cell lung cancers were investigated for the expressions of Fhit and p53 by immunohistochemistry. Marked
reduction of Fhit immunoreactivity (o10% positivity) in 156 (59%) tumours and overexpression of p53 protein (410% positivity) in
89 (34%) tumours were found. Reduced Fhit expression was also noted in most squamous cell carcinomas (80 out of 99, 81%), and
in a smaller fraction of adenocarcinomas (76 out of 164, 46%; Po0.001). p53 nuclear staining was demonstrated in 54 out of 99
(55%) squamous cell carcinomas and in 35 out of 164 (21%) adenocarcinomas (Po0.001). The loss of Fhit expression and p53
overexpression was significantly more common in tumours occurring in smokers (93 out of 113, 82% and 56 out of 113, 50%) than in
those of nonsmokers (63 out of 150, 42%; Po0.001 and 33 out of 150, 22%; Po0.001). Notably, p53 overexpression was associated
with distant metastasis of patients in the whole series (P¼0.027) and in adenocarcinoma (P¼0.001). It was also associated with a
poorer survival of patients with adenocarcinoma (P¼0.032).
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Lung cancer is the most common cause of cancer death in Taiwan
(Lee et al, 2002). It is generally believed that cancer is the end
result of a multistep process involving the activation of dominant
oncogenes and the inactivation of tumour suppressor genes.
Recent advances in the molecular genetics of human cancers have
revealed that multiple tumour suppressor genes are involved in
lung carcinogenesis (Yokota and Sugimura, 1993). The cloning of
the fragile histidine triad(FHIT) gene at 3p14.2 in 1996 (Ohta et al,
1996) and the subsequent reports demonstrated frequent allelic
deletion, aberrant FHIT transcripts in primary lung cancers (Fong
et al, 1997), cell lines of small cell and nonsmall cell type
(Yanagisawa et al, 1996). The evidence that FHIT suppresses
tumorigenicity in cancer cells (Siprashvili et al, 1997) supports the
contention that FHIT is a tumour suppressor gene. This, together
with the recent observation (Sozzi et al, 1997a) that there is more
FHIT allelic loss in carcinomas from smokers than from
nonsmokers, strengthens the case for its involvement in the
multistage development of lung cancer.
TP53, on the other hand, is a well-established inducer of
apoptosis and a major checkpoint protein involved in DNA,
spindle, and centrosome surveillance. Alteration of TP53 genes has
been among the most commonly observed tumour genetic changes
that have been closely related to the initiation and progression of a
diverse group of human cancers, including lung cancer (Levine
et al, 1991). The prevalent type of mutation is also related to DNA
adducts of benzo(a)pyrene from cigarette smoking (Denissenko
et al, 1996).
There are several reports on the correlation between abnorm-
alities of the FHIT and TP53 gene and clinicopathological features
in lung cancers. Loss of heterozygosity (LOH) at the FHIT gene
locus in adenocarcinoma was less frequent than that in squamous
cell carcinoma (Burke et al, 1998). The correlation between LOH at
the FHIT gene locus and the patients’ survival is controversial
(Fong et al, 1997; Sozzi et al, 1997a,b; Burke et al, 1998; Tomizawa
et al, 1998). LOH at the FHIT gene locus in smokers occurred more
frequently than that in nonsmokers (Sozzi et al, 1997a; Zienold-
diny et al, 2001). It was also reported that there was no correlation
between Fhit protein expression with the histotype, tumour stage,
survival (Sozzi et al, 1997a; Geradts et al, 2000) and abnormalities
of immunohistochemical expression of p53, Rb, and p16 (Geradts
et al, 2000). However, further large studies of association of FHIT
and TP53 alterations with clinical parameters are warranted.
Since immunohistochemical detection has the advantage of
detecting protein loss regardless of the underlying mechanism, it
represents an efficient method of identifying functional protein
inactivation. In this study, the expression of Fhit and p53 protein
by immunohistochemistry (IHC) in 263 surgically resected
NSCLCs were investigated. These findings were correlated with
the clinicopathological features, including smoking history,
histologic types and differentiation, tumour size, stage, tumour
emboli, tumour invasion, distant metastasis, and survival.
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Lung cancer patients and specimens
A total of 263 lung cancer specimens were obtained from patients
who underwent surgical resection for NSCLC at the National
Taiwan University Hospital for the period from January 1996 to
December 2000. These patients were not treated with neoadjuvant
chemotherapy and irradiation therapy. All the specimens were
formalin fixed and sectioned for microscopic examination after
applying haematoxylin–eosin stain. Histological diagnosis and
pathological features were obtained, including tumour cell type,
degree of differentiation, tumour emboli, direct invasion to
surrounding structures, and regional lymph node metastasis.
Pathological staging was performed according to the international
staging system for lung cancer (Mountain, 1986), which is based
on tumour size, location and involvement, and the presence of
lymph node metastases.
This study included 143 male and 120 female patients, and the
mean age was 64 years (ranging from 30 to 83 years). The clinical
data of these patients, including sex, age, smoking status, location
of the tumour, and ensuing distant metastases after surgery were
recorded, and correlated with the result of Fhit or p53 protein
expression in each tumour. No information was available for
distant metastasis in nine patients, and for tumour size and stage
in one patient. The 15-stage IIIB cases included 12 multifocal
carcinomas within one pulmonary lobe, two cancers with
pulmonary artery and aortic invasions, and one with mediastinal
involvement. All the nine stage IV cases were multifocal
carcinomas involving two pulmonary lobes.
Immunohistochemistry
For immunohistochemical demonstration of the Fhit or p53
protein expression in the tumour tissue, 4-mm-thick sections from
each formalin-fixed, paraffin-embedded tissue block were dewaxed
with xylene and rehydration through a graded series of ethanol.
The sections for IHC of the Fhit protein expression were
autoclaved in 0.01 M phosphate citrate buffer (pH 6.0) at 1211C for
3min and were treated with 3% H2O2–methanol solution to
reduce endogenous peroxidase activity. These were then incubated
with normal goat serum to reduce nonspecific antibody binding
and were subsequently subjected to the primary antibody reaction.
The antibody for Fhit protein (IBL, Gunma, Japan, 1:20) was left
to react with the sections overnight at 41C. Detection of the
immunoreactive staining was carried out by the avidin–biotin–
peroxidase complex method according to the manufacturer’s
instructions (Dako Corporation, Carpinteria, CA, USA). To check
for nonspecific staining by the avidin–biotin–peroxidase complex
detection system, the primary antibody was replaced with BSA.
The sections were then subjected to a colour reaction with 0.05%
3,3-diaminobenzidine in 0.05 M trishydrochloride (pH 7.6) con-
taining 0.01% H2O2 and were lightly counterstained with
haematoxylin.
For IHC of the p53 protein expression in the tumour tissue, the
paraffin-embedded tissue block was treated with 0.3% H2O2 in
methanol to block endogenous peroxidase, and heated in a
microwave oven for 20min for antigen retrieval. The tissue
sections were then incubated with normal nonimmune goat serum.
After blotting the excessive goat serum, the slides were incubated
with a specific mouse anti-p53 protein antibody ‘p53 (Ab-6),
pantropic’ (diluted 1:50) (Oncogene Science, Cambridge, MA,
USA) for 1h at room temperature. After washing with a
phosphate-buffered solution (PBS) three times, the sections were
incubated with biotinylated goat anti-mouse antibody for 20min at
room temperature. The sections were again washed three times
with PBS, and were then incubated with peroxidase-conjugated
steptavidin for 15min at room temperature. After a third triple
washing with PBS, the sections were then stained with 0.05% 30,3-
diaminobenzidine tetrachloride freshly prepared in 0.05 M Tris-
HCl (pH¼7.6) containing 0.01% H2O2. Finally, the sections were
counterstained with haematoxylin and then mounted.
Immunostaining was classified into the following three groups
according to both intensity and extent: (1) negative, no staining
was present, or positive staining was detected in o10% of the
cells; (2) positive staining in a range of 10–50% of cells stained;
and (3) positive immunostaining was present in 450% of the cells.
Two independent pathologists (Y-LC and C-TW) were involved in
the assessment of expression.
Statistical analysis
The correlation between various clinical or pathological para-
meters with the expression of Fhit or p53 protein was analysed
using Pearson’s w
2, Fisher’s exact, and log-rank tests. All the
statistical tests were two sided.
RESULTS
Fhit protein expression
In the current study, Fhit cytoplasmic reactivity was detected in
107 out of the 263 lung cancers (41%), usually of moderate-to-
strong intensity. The remaining 156 lung cancers (59%) were
characterised by complete absence of cytoplasmic staining or
marked reduction (o10%) of immunoreactivity. Admixed non-
neoplastic elements (normal bronchial epithelial cells, bronchial
glands, and type II alveolar cells) served as Fhit-positive internal
controls (Figure 1). The relationship between clinical parameters
or pathological characteristics, and the frequency of Fhit reactivity
is shown in Table 1.
Fhit expression was markedly reduced in most squamous cell
carcinomas (80 out of 99, 81%) (Figure 2A). A similar loss of
expression was detected in a smaller subset of adenocarcinoma (76
out of 164, 46%). The difference in the frequency of loss of Fhit
expression between squamous cell carcinomas and adenocarcino-
mas was statistically significant (Po0.001). A loss of Fhit protein
expression was observed more frequently in patients with a
smoking history (93 out of 113, 82%) than in patients without a
smoking history (63 out of 150, 42%), and such a difference was
also statistically significant (Po0.001).
The correlation between Fhit protein expression and differentia-
tion of adenocarcinoma (Figure 3A) and squamous cell carcinoma
subtypes were then analysed. In adenocarcinoma, the loss of
Figure 1 Normal bronchial epithelium used as a positive control of Fhit
protein (original magnification  66; ABC method).
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sexpression was observed preferentially in poorly differentiated
subtypes (Figure 3B); however, the correlation did not reach
statistical significance (P¼0.083). In squamous cell carcinoma, the
correlation between Fhit protein expression and differentiation
was unclear (P¼1.000).
Furthermore, Fhit expression was also prominently lost in 100
out of 143 (70%) male patients and 56 out of 120 (47%) female
patients. This difference was statistically significant (Po0.001).
However, in this cohort of 263 Taiwanese NSCLCs, there was no
statistically significant correlation between the loss of Fhit
expression and tumour size, stage of disease, distant metastasis,
tumour emboli, direct invasion to surrounding structures, and
survival (Table 1).
p53 protein expression
Overexpression of p53 protein (410% nuclear staining) was
observed in 89 out of 263 cases (34%). The relationship between
clinical parameters or pathological characteristics, and the
frequency of p53 reactivity is shown in Table 2. p53 had
significantly higher positive results in patients with squamous cell
carcinoma subtype (54 out of 99, 55%) (Figure 2B). On the other
hand, positivity was demonstrated only in 35 out of 164 (21%) of
adenocarcinomas (Po0.001). Using Pearson’s w
2 test, the differ-
ence of p53-positive staining between smokers (56 out of 113, 50%)
and nonsmokers (33 out of 150, 22%) is significant statistically
(Po0.001). p53 overexpression was also noted in 63 out of 143
Table 1 Frequency of Fhit expression with relation to clinical parameters and pathologic characteristics
Parameters No. of patients Fhit ( ) (%) Fhit (+) (%) P-value
Patient number 263 156 (59) 107 (41)
Sex
Male 143 100 (70) 43 (30)
Female 120 56 (47) 64 (53) o0.001
Smoking history
Positive 113 93 (82) 20 (18)
(male 103; female 10)
Negative 150 63 (42) 87 (58) o0.001
(male 40; female 110)
Histologic type
Squamous cell carcinoma 99 80 (81) 19 (19)
Adenocarcinoma 164 76 (46) 88 (54) o0.001
Squamous cell carcinoma
Poorly differentiated 10 8 (80) 2 (20)
Others 89 72 (81) 17 (19) 1.000
a
Adenocarcinoma
Poorly differentiated 9 7 (78) 2 (22)
Others 155 69 (45) 86 (55) 0.083
a
Tumour size
3cm and less 120 64 (53) 56 (47)
43cm 142 91 (64) 51 (36) 0.078
Tumour stage
Stage I 124 71 (57) 53 (43)
Stages II and IIIA 114 67 (59) 47 (41)
Stages IIIB and IV 24 17 (71) 7 (29) 0.449
Tumour emboli
Positive 58 36 (62) 22 (38)
Negative 205 120 (59) 85 (41) 0.629
Tumour local invasion
Positive 62 35 (56) 27 (44)
Negative 201 121 (60) 80 (40) 0.600
Distant metastasis
Positive 99 60 (61) 39 (39)
Negative 155 88 (57) 67 (43) 0.546
p53 expression
p53 (+) 89 61 (69) 28 (31)
p53 ( ) 174 95 (55) 79 (45) 0.030
Distant metastasis in adenocarcinomas
Positive 65 33 (51) 32 (49)
Negative 97 42 (43) 55 (57) 0.350
aFisher’s exact test. Others: Pearson’s w
2 test.
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addition, p53 had significantly higher positive results in patients
with distant metastasis (P¼0.027) in the overall NSCLCs and in
the adenocarcinoma subset (P¼0.001) (Table 2), as well as a
poorer survival of patients with adenocarcinoma (log-rank test
P¼0.032) (Figure 4).
Correlation of Fhit expression with p53 protein expression
abnormalities
The correlation between Fhit and p53 protein expression has not
been previously studied in detail. These results indicate that FHIT
and TP53 gene alterations by Pearson’s w
2 test are concordant and
preferentially occur in squamous cell carcinomas, among smokers,
and in male patients (Tables 1 and 2).
DISCUSSION
It is well documented that specific genetic alteration and aberrant
gene expression in tumour cells may influence its biological
behaviour (Levine et al, 1991). The genomic status of FHIT and
TP53 genes has been investigated in a series of lung cancers.
Deletions at the chromosomal region 3p14.2 and TP53 abnorm-
alities were present in 20% of the cases and the alterations were
constantly associated (Marchetti et al, 1998). Recently, it was
reported that alterations in the FHIT locus detected by DNA and/
or reverse transcription–PCR analysis correlated with a loss of
Fhit protein expression in lung, cervical, and breast carcinomas
(Greenspan et al, 1997; Sozzi et al, 1997b; Campiglio et al, 1999).
The results indicated that FHIT gene alterations could easily be
detected by immunohistochemical analysis of tumour specimens.
Altered Fhit expression is the most frequent genetic change in
lung tumours. No major impact of Fhit expression on prognosis
and other clinical parameters were observed. This finding indicates
that the inactivation of the FHIT gene is involved in the early
phases of lung carcinogenesis and hence, is more likely related to
the initiation of the neoplastic process rather than to the
progression, invasiveness, or distant metastasis.
TP53 is a tumour suppressor gene, involved in cell cycle control
and the preservation of genomic integrity (Levine et al, 1991;
Zambetti et al, 1993). Alteration of the TP53 gene may be involved
in the initiation, development, progression, and invasion of lung
cancer (Caamano et al, 1991; Sozzi et al, 1992; Marchetti et al 1993;
Fontanini et al, 1994). Even though correlation of p53 protein
expression with clinical and biological characteristics of lung
cancer has been extensively studied, the results of these studies are
quite diverse (Top et al, 1995; Passlick et al, 1995; Dalquen et al,
1996; Lee et al 1999; Garinis et al, 2001; Zienolddiny et al, 2001).
Figure 2 Squamous cell carcinoma of a smoker. (A) Loss of Fhit
expression (original magnification  33; ABC method). (B) Overexpres-
sion of nuclear staining for p53 (original magnification  33; ABC method).
Figure 3 Fhit immunoreactivity in adenocarcinoma. (A) Strong Fhit
cytoplasmic immunoreactivity in a well-differentiated adenocarcinoma
(original magnification  66; ABC method). (B) Weak or negative Fhit
immunoreactivity in the less differentiated adenocarcinoma (original
magnification  33; ABC method).
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related to distant metastasis of the overall NSCLCs and the
adenocarcinoma subtype; and p53 was especially useful as a
prognostic factor in adenocarcinoma. This observation had never
been reported before.
Fhit protein expression was markedly reduced in most
squamous cell carcinomas, and such a reduction was significantly
more frequent in the squamous cell carcinoma subtype than in the
adenocarcinoma subtype. Furthermore, a marked reduction of Fhit
protein expression was observed more frequently in patients with
positive smoking histories than in patients with negative smoking
histories. These data indicate that FHIT gene alterations prefer-
entially occur in squamous cell carcinomas and in smokers. On the
other hand, p53 overexpression is also significantly more common
in tumours occurring in smokers than in those of nonsmokers.
This constant association of Fhit and p53 abnormalities in tumours
from smoking subjects is intriguing.
Loss of Fhit expression appears to be strongly associated with
smoking status, suggesting that the FHIT gene may be the target of
carcinogens in cigarette smoke. The study by Sozzi et al (1997a)
indicates that FRA3B is a preferential target of tobacco smoke
damage at a molecular level. This suggests that loss of Fhit
expression is due to damage at the fragile locus, resulting in FHIT
loss. According to Burke et al (1998), the statistical associations
among FHIT allelic deletion and TP53 missense mutations might
be explained by the damage caused by tobacco smoke carcinogens.
This is shown by the fact that TP53 mutations are more common
in centrally located squamous cell carcinomas than in the
peripheral adenocarcinomas (Greenblatt et al, 1994). A plausible
explanation is the presence of an increased dosage of chemical
carcinogens in the central airways compared with those present in
peripheral lung tissues.
In vitro evidence for chemical carcinogenesis models linking
carcinogen–DNA adducts to hotspots of TP53 missense mutations
Table 2 Frequency of p53 expression with relation to clinical parameters and pathologic characteristics
Parameters No. of patients P53 (+) (%) P53 ( )( % ) P-value
Patient number 263 89 (34) 174 (66)
Sex
Male 143 63 (44) 80 (56)
Female 120 26 (22) 94 (78) o0.001
Smoking history
Positive 113 56 (50) 57 (50)
(Male 103; Female 10)
Negative 150 33 (22) 117 (78) o0.001
(Male 40; Female 110)
Histologic type
Squamous cell carcinoma 99 54 (55) 45 (45)
Adenocarcinoma 164 35 (21) 129 (79) o0.001
Squamous cell carcinoma
Poorly differentiated 10 6 (60) 4 (40)
Others 89 48 (54) 41 (46) 0.752
a
Adenocarcinoma
Poorly differentiated 9 1 (11) 8 (89)
Others 155 34 (22) 121 (78) 0.686
a
Tumour size
3cm and less 120 41 (34) 79 (66)
43cm 142 48 (34) 94 (66) 0.951
Tumour stage
Stage I 124 41 (33) 83 (67)
Stages II and IIIA 114 42 (37) 72 (63)
Stages IIIB and IV 24 6 (25) 18 (75) 0.515
Tumour emboli
Positive 58 21 (36) 37 (64)
Negative 205 68 (33) 137 (67) 0.666
Tumour local invasion
Positive 62 22 (35) 40 (65)
Negative 201 67 (33) 134 (67) 0.754
Distant metastasis
Positive 99 40 (40) 59 (60)
Negative 155 42 (27) 113 (73) 0.027
Distant metastasis in adenocarcinomas
Positive 65 22 (34) 43 (66)
Negative 97 12 (12) 85 (88) 0.001
aFisher’s exact test. Others: Pearson w
2 test.
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et al, 1996), and analysis of human cancer cell deletion end points
shows that the FRA3B fragile site is a common target of
homologous recombination producing FHIT internal deletions
(Inoue et al, 1997). Taken together, these results provide a direct
link between specific genetic alterations and exposure to tobacco
carcinogens. As in the reports mentioned before (Marchetti et al,
1998; Geradts et al, 2000), Fhit expression was not correlated to the
abnormality of p53 in smoking patients. A recent study
(Zienolddiny et al, 2001) indicated that LOH at 3p, 5q, 9p, 11p,
and 17p regions were interdependent and highly associated with
mutated TP53 gene in smokers. The significant association of Fhit
and p53 protein expressions with smokers in the present study is
perhaps related to the size of this series.
It is also noted that a loss of Fhit protein expression and p53
overexpression was significantly associated with male patients. The
meaning of this association is not clear and has never been
reported before. The possible explanation for such a phenomenon
is that the smokers in our series are nearly all male patients and
only 10 female patients were smokers. Thus, additional evaluation
of Fhit and p53 protein expressions performed in a series with
more female smoking patients would clarify this relationship in the
future.
Interestingly, a reduction of Fhit expression was more
commonly detected in the less differentiated areas of the
adenocarcinoma than in the more differentiated cells . Although
this difference did not have statistical significance, this observation
is still suggestive of the possibility that Fhit protein expression is
related to the degree of differentiation or the stage of progression
in the adenocarcinoma subtype (Tomizawa et al, 1998).
In conclusion, this study is the first to demonstrate the
concurrent loss of Fhit expression and p53 overexpression in
squamous cell carcinoma and smokers by IHC. These alterations
in expression also suggest a role in the initiation of smoking-
related lung tumourigenesis. Likewise, there is an association
between the pattern of Fhit expression and the level of cell
differentiation in adenocarcinoma. Interestingly enough, the
present results also have clinical implications due to the
observation of a statistically significant trend towards distant
metastasis and poorer survival in adenocarcinoma patients with
p53 overexpression. Thus, it is strongly indicated that p53
overexpression could be a useful prognostic marker for surgically
resected adenocarcinoma.
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